5-MeO-DMT and Postpartum Depression: A Closer Look at the "100% Remission" Study
- A small trial gave inhaled 5-MeO-DMT to ten women with postpartum depression and reported that every one of them reached remission within a single day. The number is dramatic. The study behind it is tiny and uncontrolled.
- The standard alternative, daily SSRIs, crosses the placenta and shows up in breast milk, often for months or years. In head-to-head studies it performs about as well as exercise, and its edge over placebo is small outside of severe depression.
- 5-MeO-DMT is not new. It is an old tryptamine with deep roots in plant snuffs and toad medicine, and it clears the body in hours rather than days.
- The design has real holes: no placebo group, no blinding, a one-week window, funding from the company that makes the drug, and remission scored while the afterglow of the experience was arguably still fresh.
- This sits inside a wider wave of research into psilocybin, ibogaine and related compounds for depression and PTSD. I am hopeful about the direction and unconvinced by the headline.
The study, in plain terms
Roughly one in five new mothers develops postpartum depression. For many, it does not lift quickly. A meaningful share are still struggling two years out. And the usual help is slow.
So a new trial in the Journal of Clinical Psychiatry landed hard. Researchers gave inhaled 5-MeO-DMT, a synthetic version called GH001, to ten women with moderate-to-severe postpartum depression. By day eight, all ten met the study's bar for remission. You can read the full open-access paper here.
The women came in averaging about 37 on the MADRS, a clinician-rated depression scale where higher means worse. A week later, scores had fallen by about 35 points. Suicidal thoughts, present in three of them at the start, were gone by the end of dosing day. A separate measure of how well a mother can function and care for her baby rose by more than half. Side effects were mild, mostly headache. Everyone went home the same day.
That is a striking picture. It is also ten women, with no comparison group. Hold both of those thoughts at once, because the rest of this piece lives in the space between them.
An old molecule wearing a lab coat
It is tempting to read 5-MeO-DMT as a shiny new drug. It isn't. The molecule, formally called mebufotenin, shows up in certain plants and in the defensive secretions of the Sonoran Desert toad. Long before any clinic touched it, Indigenous peoples across South America and the Caribbean were preparing tryptamine-rich snuffs like yopo and cohoba for ceremony and healing.
There is an evolutionary logic to why it does anything at all. Our brains are covered in serotonin receptors, and plant and animal tryptamines slot into them. 5-MeO-DMT favors one called 5-HT1A, rather than the 5-HT2A receptor behind the long visual journeys of psilocybin. The practical result is a very short experience, usually under 45 minutes, that seems to work by briefly opening the brain to change rather than by hours of altered perception. "Neuroplasticity" is the word researchers keep reaching for. It just means the brain's ability to rewire and form new connections.
Two worlds are trying to do the same job here. One holds a person through a powerful state with ritual and a human guide. The other does it with a vaporizer and a blood-pressure cuff. Worth keeping that contrast in mind.
The hormonal cliff almost no one prepares you for
Pregnancy floods the body with estrogen and progesterone. Within a day or two of birth, those levels fall off a cliff. The drop is one of the most abrupt hormonal shifts a human body goes through, and the brain feels it.
This is not fringe thinking. It is the reason the two drugs approved specifically for postpartum depression target a progesterone byproduct called allopregnanolone, a calming molecule that crashes along with everything else after delivery. Traditional postpartum systems understood the fragility of this window in their own language. Chinese "sitting the month" and Ayurvedic postpartum care both center the same things: rest, warmth, deeply nourishing food, and a circle of people taking work off the mother. Modern life often hands her the opposite. Isolation and a quick return to function.
The crash can hit harder when birth itself was heavily managed. Induction, synthetic oxytocin, surgical delivery and the rest can interrupt the natural hormonal cascade that surrounds labor, including the body's own oxytocin surge that supports bonding and mood. The research linking birth interventions to later depression is mixed and tangled with other factors, so I hold it loosely. But the basic point stands. A body that was rushed or overridden may have a steeper hill to climb afterward.
There is a metabolic thread here too, one that herbalists and a handful of doctors have flagged for decades. The thyroid shifts dramatically around birth, and postpartum thyroid trouble is common and easy to miss. Broda Barnes spent a career arguing that low thyroid function hides behind a great deal of fatigue and low mood. Ray Peat kept the focus on the whole hormonal and metabolic terrain, progesterone and thyroid and cellular energy, rather than serotonin alone. A trial that enrolls only women with no other conditions and watches them for a week is not built to ask whether some of these mothers had an unrecognized thyroid or metabolic driver. That is a gap in the field, not a knock on this one study.
What we actually hand mothers right now
To judge whether a single-day treatment is exciting, you have to be honest about the current standard. It is not as clean as the prescription pad suggests.
The first-line option is an SSRI, a daily antidepressant that raises available serotonin. Two things about SSRIs rarely make it into the conversation at the clinic. They cross the placenta, with transfer in pregnancy that can approach the mother's own dose, and they pass into breast milk. The amount in milk is lower, but here is the part that gets lost. These are taken every single day, often for months or years. The 5-MeO-DMT in this trial was measurable in breast milk for a matter of hours. The long-term effects of steady fetal and infant exposure to SSRIs are still described in the literature as unclear. We are medicating a developing brain and calling the unknowns acceptable.
And the benefit we are trading those unknowns for is smaller than most people assume. In head-to-head comparisons, exercise performs about as well as antidepressants for non-severe depression. When researchers pooled the full set of trials submitted to regulators, including the unpublished ones, the gap between drug and placebo turned out to be small at moderate severity and only crossed into clinical significance at the very severe end. A daily pill, for an effect that movement often matches.
Then there are the harms people are not warned about. Sexual side effects during SSRI treatment are common, with estimates ranging widely and reaching up to roughly two-thirds of users in some samples. For a subset, the trouble does not end when the pills do. A recognized condition called post-SSRI sexual dysfunction involves lingering numbness, loss of orgasm and emotional blunting that can persist for months or years after stopping. Its exact prevalence is still being worked out, but it is real enough that regulators in Europe, Canada and Australia have added warnings to the labels. Emotional flatness, the sense of not quite being able to feel, is part of the same picture.
Stopping is its own ordeal. Antidepressant withdrawal is now formally recognized, and systematic reviews put the share of people who get discontinuation symptoms anywhere from around 15 percent up to half, depending on how you count. Brain zaps, dizziness, nausea, insomnia, waves of dread. The drugs do not produce a high, so "addictive" is the wrong word, but they can create real physical dependence. Most pills are not even made in doses small enough to taper gently, and many prescribers were never taught how. The slow, hyperbolic reductions that work best are something patients often have to discover on their own.
None of this means SSRIs help no one, and untreated severe depression is genuinely dangerous, which is exactly why no one should come off a medication abruptly or alone. The point is narrower and harder to dodge. We need safer options than a class of drugs that is habit-forming in the dependence sense, of debatable benefit in milder cases, and carrying risks that can outlast the prescription. That is the vacuum a fast, short-lived compound is stepping into.
How the study was built
Design is where a headline either earns its keep or doesn't. Here is what the team did.
They enrolled women aged 18 to 45 who met formal criteria for depression with onset around childbirth and scored at least 28 on the MADRS. On one day, each received up to three escalating doses through an inhalation device, with about an hour between them. A later dose only came if the previous one was tolerated and had not already produced an intense peak experience. No formal psychotherapy was attached, before, during or after.
That last choice is a real strength. Many psychedelic studies bundle the drug with hours of skilled therapy, which makes it impossible to know which one did the work. Stripping the therapy out isolates the molecule. The team also did serious safety monitoring, including heart tracing, lung function, bloodwork and cognitive testing. And for the four women still nursing, they measured the compound in breast milk. It was detectable about an hour after dosing and near zero by roughly eight hours, which points to a short pause in breastfeeding rather than weaning. For a nursing mother, that detail is the whole question, not a footnote.
The flaws the headline hides
I want to be fair to this trial and clear-eyed about it. It is a legitimate early study. It is nowhere near what the internet is implying.
| What is promising | What seriously limits it |
|---|---|
| Large, fast effect, with several different measures moving together. Harder to fake than one number. | Ten women. The team wanted fifteen and stopped early. Tiny samples make percentages look cleaner than reality. |
| Suicidal thoughts dropped to zero by the end of dosing day, which matters enormously here. | No placebo, no blinding. Everyone knew they got the real thing, so expectancy, natural recovery and regression to the mean (extreme scores drifting back toward average on their own) cannot be ruled out. |
| Thorough safety monitoring, no serious adverse events, same-day discharge. | The maker, GH Research, designed and funded it, and many authors are employees and stockholders. A real conflict of interest, not a disqualifier, but it belongs in daylight. |
| Breast-milk data answers a question nursing mothers genuinely need answered. | Ninety percent White, one-week follow-up, and women on antidepressants or with other conditions were excluded. Real-world postpartum depression is messier. |
One flaw deserves its own spotlight, and it is the one your gut probably already caught. Remission was first scored two hours after the final dose, then at day two, then at day eight. The molecule clears the body in hours, but the afterglow of a profound experience does not, and neither does expectancy. Scoring someone's depression while they are still glowing from a peak experience tells you they feel transformed today. It does not tell you whether it lasts. Even day eight is short. The honest test is where these women are at one month, three months, six. The study simply does not go there, and that is the difference between a durable reset and a temporary lift.
There is also a problem that haunts the whole field. A compound that produces an unmistakable altered state is nearly impossible to blind, because people can tell whether they got it. Solving that "functional unblinding" well is part of what will separate a convincing future trial from a flattering one.
Support Us by Shopping Our Store
Sites like mine are often suppressed because they don’t always align with the “narrative”. Shop our storefront to support us directly, or share this article with a friend.
Frog versus lab: two imperfect paths
Because the toad keeps coming up, it is worth weighing the traditional source against the pharmaceutical one honestly. Neither is clean.
| Traditional (toad or plant) | Pharmaceutical (GH001) |
|---|---|
| Held inside ritual and meaning, with an experienced guide tending set and setting. | Stripped of that container. A clinical room and a questionnaire, not a ceremony. |
| Whole-substance, with the co-occurring compounds some traditions consider part of the medicine. | A single isolated molecule. Reproducible, but the "whole versus isolate" debate that runs through all of herbalism applies here too. |
| Toads can be stressed or harmed in harvesting, and wild collection raises conservation concerns. | No animal touched. Synthesized in a lab. |
| Dosing is intuitive and inconsistent. Potency varies, purity is unknown, contamination is possible. | Consistent and exact, but rigid. Manufacturing carries its own risks, from processing residues to formulation additives. |
| No medical monitoring if something goes wrong. | Sterile setting with vitals tracked, plus commercial and patent incentives shaping how it gets studied and sold. |
My own bias leans toward the whole, the contextual, the relational. But I will not pretend a foraged toad secretion is automatically safer than a measured dose in a monitored room. The traditional path offers meaning and a guide. The pharmaceutical path offers consistency and a safety net. The honest answer is that something real is lost when a plant or animal medicine is reduced to a molecule, and something real is gained. Both can be true.
A wider psychedelic moment
This study is not happening in isolation. After decades of prohibition, compounds that nudge the brain toward plasticity are getting a serious second look for the conditions conventional drugs handle worst.
Psilocybin has the most data, with randomized trials in treatment-resistant depression and early signals for PTSD. One open-label study even followed veterans for a full year after a single dose, which is exactly the kind of long horizon the 5-MeO-DMT trial lacked. Ibogaine, from the African iboga shrub, is being studied for addiction and for trauma in veterans. As of 2026 the FDA has even begun clearing the way for studies of psilocybin, an ibogaine derivative and others.
The common thread is plasticity. Andrew Huberman and others have helped popularize the idea that these compounds may pry open a brief window when the brain is unusually able to reorganize. If that is the mechanism, then what surrounds the window, the rest and nourishment and relationships and the meaning a person makes of it, may matter as much as the molecule. Which is a very old idea in modern dress.
Why I am hopeful anyway
I can be skeptical of the headline and excited about the road. Those are not in tension.
What draws me in is the shape of the thing, not the marketing. A treatment that clears in hours, needs no daily pill, and might be repeated occasionally rather than taken forever is a fundamentally different proposition than years on an SSRI. The maternal-functioning signal is the part I would chase hardest, because a mother's depression is never only hers. It reaches into the bond with her baby. If future work can measure that bond directly, with real control groups and a follow-up measured in months, it would tell us something a depression score never can.
The study I want to see is the one this team could not run. Larger and more diverse. Truly placebo-controlled. Honest about how much credit belongs to the molecule versus the care and meaning around it. Attentive to thyroid and metabolic health, which the rush past biochemistry tends to ignore. Those are the questions a perspective rooted in traditional medicine is well placed to ask. For now, this trial earned the right to a bigger one. That is all it earned, and it is not nothing.
Frequently asked questions
What is 5-MeO-DMT?
5-MeO-DMT, also called mebufotenin, is a fast-acting tryptamine found in some plants and in the secretions of the Sonoran Desert toad. It acts on serotonin receptors, especially the 5-HT1A subtype, and produces a brief but intense altered state.
How is it different from psilocybin?
Psilocybin, the compound in "magic mushrooms," lasts several hours and works mainly through the 5-HT2A receptor. 5-MeO-DMT is far shorter, usually under an hour, and favors 5-HT1A. That short duration is one reason researchers see it as a lower-burden option.
Did the study prove 5-MeO-DMT treats postpartum depression?
No. It was a small, early, open-label trial of ten women, with no placebo group, a one-week follow-up, and funding from the drug's maker. It is a promising signal that justifies larger, controlled research, not a proven treatment.
Why is a one-week follow-up a problem?
Because remission was measured within hours of dosing and again at one week, while the afterglow of the experience and the expectation of feeling better were still strong. A short window cannot tell a lasting change from a temporary lift. Effects measured at one, three and six months would be far more convincing.
Do SSRIs pass into breast milk and across the placenta?
Yes. SSRIs cross the placenta during pregnancy, with transfer that can approach the mother's dose, and they appear in breast milk at lower levels. Unlike a single dose of 5-MeO-DMT, they are taken daily, often for long stretches, and the long-term effects of that steady exposure on a developing brain are still not well understood.
Does 5-MeO-DMT pass into breast milk?
In this trial it was detectable in breast milk about an hour after dosing and dropped to near zero by roughly eight hours. The researchers suggested a brief pause in breastfeeding around dosing may be enough, though this is preliminary.
Is 5-MeO-DMT legal?
In most countries, including the United States, it is a controlled substance. In this study it was given only in a supervised medical setting. This article is educational and is not a suggestion to seek out or use it.
What is the MADRS score?
The Montgomery-Asberg Depression Rating Scale is a clinician-rated measure of depression severity. Higher scores mean worse symptoms, and a score of 10 or below was the study's threshold for remission.
What other psychedelics are being studied for depression and PTSD?
Psilocybin has the most clinical data for treatment-resistant depression, with early work in PTSD. Ibogaine is being studied for addiction and trauma. Ketamine is already in clinical use. Most of this interest centers on the same idea: briefly boosting the brain's capacity to rewire.
Source: Johnson M, et al. Inhaled mebufotenin (GH001) for adult patients with postpartum depression: a phase 2a open-label clinical trial. J Clin Psychiatry. 2026;87(3):25m16284. Full text. Trial registration: ClinicalTrials.gov NCT05804708.
